Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.
(Bloomberg) -- Sign up for the New Economy Daily newsletter, follow us @economics and subscribe to our podcast.Most Read from BloombergCannabis Compounds Prevented Covid Infection in Laboratory StudyFrequent Boosters Spur Warning on Immune ResponseSupreme Court Blocks Biden’s Shot-or-Test Rule for WorkersSay Goodbye to Self-Isolating, WFH Mandates, Mass TestingDjokovic’s Australian Visa Canceled Again in Public InterestGermany’s economy contracted by as much as 1% in the final quarter of 2021 as
In what hardly qualifies as a surprising development, shares of both Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) fell in price on Thursday. This was on the back of a Supreme Court decision that struck down a key government vaccination mandate. After the smoke cleared, Pfizer's stock price fell by nearly 2%, while the far smaller and less diversified BioNTech suffered an 8% hit.